ELI LILLY & Co 4

Director J. Erik Fyrwald deferred $1,183.16 of director fees into Eli Lilly & Co common stock units under a compensation plan, increasing his direct holdings to about 75,418 shares/units.

On August 17, 2026, director J. Erik Fyrwald of Eli Lilly & Co elected to receive $1,183.16 of cash compensation in the form of deferred stock units under the Lilly Directors' Deferral Plan, resulting in an acquisition (coded "A" on Form 4) of common stock units at an implied reference value of $8.3815 per unit. These stock units are deferred and will be settled in shares of common stock only after his separation from service, and are reported as directly owned, bringing his total direct holdings to approximately 75,418.1248 units/shares. Using the current market price of $1,225.34 per share, his post‑transaction holdings are valued at roughly $92.4 million, indicating this filing reflects routine director compensation deferral rather than an open‑market purchase or sale.

Filing Facts

CIK

59478

Ticker

LLY

Form

4

Source Type

fda

Accession

0000059478-26-000085

Alert Tier

4